Sequential Versus Step-Therapy Approaches for Osteoporosis Management in Orthopedic Subspecialties Authors: Samer G Salman, Rohan Phadke, James Burnett, Jonathan Walsh Published: 2026 ABSTRACT AbstractPurpose of Review Osteoporosis affects more than 53 million Americans and contributes to nearly 2 million fragility fractures each year, yet most patients who sustain fractures never receive guideline-recommended pharmacotherapy. Traditional step-therapy typically begins with bisphosphonates and reserves anabolic agents for later-line use, whereas sequential therapy prioritizes anabolic treatment followed by antiresorptive consolidation. This review synthesizes the evidence comparing these treatment paradigms and examines their relevance to orthopedic populations, in whom bone quality directly influences fracture healing, fixation, fusion, and implant-related outcomes.Recent Findings Among 37 studies meeting PRISMA-ScR inclusion criteria, anabolic-first sequential therapy generally produced greater gains in bone mineral density and greater fracture risk reduction than step-therapy or antiresorptive monotherapy. In one representative trial, romosozumab followed by denosumab achieved a 16.8% increase in lumbar spine bone mineral density versus 7.5% with monotherapy, and 92% versus 47% of patients reached treatment targets. In ARCH, anabolic-first therapy was associated with 48% lower vertebral fracture risk and 38% lower hip fracture risk. In orthopedic settings, emerging evidence suggests that sequential protocols may improve postoperative bone mineral density after hip fracture, support spinal fusion, and mitigate periprosthetic bone loss after arthroplasty. Prior antiresorptive exposure appeared to attenuate subsequent anabolic response, particularly at the hip, supporting the rationale for earlier anabolic use. Economic analyses also suggest that, despite higher upfront drug costs, sequential therapy may be cost-effective in patients at high fracture risk.Summary Current evidence supports anabolic-first sequential therapy as a more effective strategy than step-therapy for improving bone mineral density and reducing fracture risk in appropriately selected high-risk patients. For orthopedic populations, the available data suggest meaningful potential benefits in hip fracture care, spinal reconstruction, and arthroplasty, although subspecialty-specific evidence remains more limited than the broader osteoporosis literature. These findings support reconsideration of formulary and treatment policies that delay anabolic therapy in patients most likely to benefit. Introduction Osteoporosis represents a substantial and growing burden on global healthcare systems, characterized by compromised bone strength that predisposes individuals to fragility fractures. In the United States alone, approximately 10 million individuals carry a diagnosis of osteoporosis, while an additional 43.4 million exhibit low bone mass, collectively placing enormous strain on healthcare infrastructure [1]. Each year, approximately two million fragility fractures occur; yet, alarmingly, 76% of these patients do not receive recommended pharmacological therapy following their injury [2, 3]. This persistent clinical care gap is particularly consequential in orthopedic subspecialties, where skeletal integrity fundamentally determines surgical success, implant longevity, and patient survival. The traditional pharmacological approach to osteoporosis management, commonly termed step-therapy or step-up therapy, involves initiating treatment with the least expensive oral antiresorptive agents, most commonly bisphosphonates and escalating to more potent or anabolic therapies only when patients fail treatment, typically defined by the occurrence of a new fracture or significant decline in bone mineral density (BMD) [4]. However, emerging evidence and contemporary consensus from leading professional organizations including the American Society for Bone and Mineral Research (ASBMR), the International Osteoporosis Foundation (IOF), and the American Association of Clinical Endocrinologists (AACE) increasingly suggest that this reactive model is fundamentally flawed for high-risk populations [4, 5]. An alternative paradigm, sequential therapy, prioritizes the initial use of bone-forming (anabolic) agents followed by bone-resorption inhibitors (antiresorptives). This approach has demonstrated superior efficacy in rapidly optimizing BMD targets and reducing subsequent fracture risk [6]. The physiological rationale for this sequence stems from the observation that anabolic agents build new bone architecture that antiresorptives cannot create, while antiresorptives consolidate these gains by preventing subsequent resorption [6, 7]. Furthermore, the effectiveness of anabolic agents may be significantly attenuated when administered following prolonged antiresorptive exposure, a phenomenon termed the blunting effect [7, 8]. Despite growing mechanistic and clinical evidence supporting sequential therapy, step-therapy remains the dominant model in clinical practice, largely driven by formulary restrictions and cost considerations. The purpose of this scoping review is to synthesize the available evidence comparing the effectiveness of sequential versus step-therapy approaches for osteoporosis management, with particular emphasis on outcomes relevant to orthopedic subspecialty populations including those undergoing hip fracture management, spinal reconstructive surgery, and total joint arthroplasty. Methods Study Design and Framework This scoping review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines [9]. The scoping review methodology was selected to map the breadth of evidence regarding sequential versus step-therapy approaches across diverse orthopedic contexts, identify knowledge gaps, and synthesize findings to inform clinical practice recommendations. Information Sources and Search Strategy A comprehensive literature search was conducted across multiple electronic databases including PubMed/MEDLINE, Embase, Cochrane Library, and Web of Science from database inception through January 2026. The search strategy combined Medical Subject Headings (MeSH) terms and keywords including: osteoporosis, sequential therapy, step therapy, anabolic agents, antiresorptive, bisphosphonates, denosumab, teriparatide, romosozumab, abaloparatide, bone mineral density, fracture prevention, and orthopedic surgery. Reference lists of included studies and relevant systematic reviews were manually searched to identify additional eligible publications. Eligibility Criteria Studies were included if they: (1) enrolled adult patients with osteoporosis or osteopenia; (2) compared sequential therapy (anabolic followed by antiresorptive) with step-therapy (antiresorptive first with or without subsequent anabolic) or monotherapy approaches; (3) reported outcomes relevant to BMD changes, fracture incidence, surgical outcomes, or cost-effectiveness; and (4) were published in English. Randomized controlled trials, prospective and retrospective cohort studies, systematic reviews, meta-analyses, and relevant clinical guidelines were eligible for inclusion. Case reports, editorials, and conference abstracts without full-text availability were excluded. Study Selection and Data Extraction The initial database search yielded 2,847 potentially relevant records. Following removal of 612 duplicates, 2,235 records underwent title and abstract screening. Of these, 347 full-text articles were assessed for eligibility, resulting in 37 studies meeting all inclusion criteria for final analysis. Two independent reviewers conducted screening and data extraction using a standardized form capturing study characteristics, patient populations, intervention protocols, outcome measures, and key findings. Discrepancies were resolved through consensus discussion. Studies were categorized thematically by: pharmacological mechanisms, BMD outcomes, fracture risk reduction, orthopedic subspecialty applications, special populations, and health economics. Results Pharmacological Mechanisms and Sequencing Rationale The included literature consistently demonstrated that the superiority of the anabolic-to-antiresorptive sequence is rooted in divergent mechanisms of bone remodeling and modeling. Osteoporosis is characterized by an imbalance where osteoclast resorptive activity exceeds osteoblast formative capacity, leading to architectural decay [10]. Antiresorptive agents function primarily by reducing the rate of bone remodeling. Bisphosphonates, including alendronate, risedronate, and zoledronic acid, bind to hydroxyapatite and inhibit farnesyl pyrophosphate synthase within osteoclasts, inducing apoptosis and effectively closing the remodeling space [11]. Denosumab, a humanized monoclonal antibody, targets receptor activator of nuclear factor-kappa B ligand (RANKL), preventing osteoclast maturation and survival [12]. In contrast, anabolic agents stimulate modeling-based bone formation. Teriparatide (PTH 1–34) and abaloparatide (PTHrP analog) transiently activate the parathyroid hormone receptor type 1 (PTH1R), preferentially stimulating osteoblastic activity and enhancing trabecular and cortical bone formation [6, 13]. Romosozumab offers a distinct dual mechanism; by inhibiting sclerostin, it transiently boosts bone formation while simultaneously providing sustained decreases in bone resorption [6]. Critically, the bone-forming response to these agents is self-limiting and plateaus after 12 to 24 months, and cessation leads to rapid reversal of BMD gains unless followed by antiresorptive consolidation [6, 14]. Multiple studies documented the blunting effect observed when anabolic agents are administered after long-term antiresorptive therapy. The STRUCTURE trial demonstrated that patients transitioning to teriparatide after prior alendronate experienced transient hip BMD loss requiring several months for recovery [8]. This phenomenon is attributed to antiresorptive-induced suppression of bone turnover, which limits the available surface area and release of skeletal growth factors necessary for anabolic agents to exert their full effect [7]. Table 1 summarizes the comparative mechanisms and sequencing impact of major osteoporosis agents. Table 1Comparative mechanisms and sequencing impactAgent ClassRepresentative DrugsPrimary MechanismStep-Therapy ImpactAntiresorptiveAlendronate, Zoledronate, DenosumabInhibits osteoclasts via FPPS inhibition or RANKL blockadeInitial choice; leads to blunting of later anabolics [36]AnabolicTeriparatide, AbaloparatidePTH1R activation; stimulates modeling-based formationEffectiveness reduced by prior antiresorptive exposure [7]Dual-ActionRomosozumabSclerostin inhibition; increases formation, decreases resorptionHip BMD gains attenuated if used after denosumab [36]Abbreviations: FPPS = farnesyl pyrophosphate synthase; RANKL = receptor activator of nuclear factor-kappa B ligand; PTH1R = parathyroid hormone receptor type 1; BMD = bone mineral density Comparative mechanisms and sequencing impact Abbreviations: FPPS = farnesyl pyrophosphate synthase; RANKL = receptor activator of nuclear factor-kappa B ligand; PTH1R = parathyroid hormone receptor type 1; BMD = bone mineral density Bone Mineral Density Outcomes The included studies consistently demonstrated superior BMD outcomes with sequential therapy compared to monotherapy or step-therapy approaches. In the FRAME study, postmenopausal women receiving 12 months of romosozumab followed by 12 months of denosumab achieved substantially higher BMD increases at 24 months compared to denosumab monotherapy [15]. At the lumbar spine, the sequential group achieved a 16.8% increase compared to approximately 7.5% in the monotherapy arm. Similarly striking results were observed at the hip, with the sequential cohort achieving 4.4% greater total hip BMD increase than the denosumab-only group [15]. The probability of achieving a treat-to-target goal (T-score better than − 2.5) was significantly enhanced by sequential therapy. For patients starting with a T-score of -3.0 at the lumbar spine, the romosozumab/denosumab sequence offered 92% probability of reaching target within 24 months, versus only 47% for denosumab monotherapy [15]. At the total hip, this discrepancy was even more pronounced: 50% probability for sequential therapy versus 5% for monotherapy [15]. Table 2 presents the 24-month BMD outcomes from the FRAME study and extension analyses. Table 224-Month BMD Outcomes: Sequential vs. MonotherapyStudy SiteRomo → DMAb (%)DMAb → DMAb (%)p-valueLumbar Spine+ 16.8+ 7.5< 0.001Total Hip+ 8.4+ 4.0< 0.001Femoral Neck+ 7.6+ 3.5< 0.001Data synthesized from FRAME and FRAME Extension post hoc analyses [15]. Abbreviations: BMD = bone mineral density; Romo = romosozumab; DMAb = denosumab; est = estimated 24-Month BMD Outcomes: Sequential vs. Monotherapy Data synthesized from FRAME and FRAME Extension post hoc analyses [15]. Abbreviations: BMD = bone mineral density; Romo = romosozumab; DMAb = denosumab; est = estimated The ACTIVE and ACTIVExtend trials evaluated abaloparatide followed by alendronate. After 18 months of abaloparatide, lumbar spine BMD increased by 11.2% compared to 10.5% for teriparatide [16]. Following transition to alendronate for an additional two years, the sequential group achieved total lumbar spine gains of 14.4% and total hip gains of 6.4% [16]. Notably, abaloparatide demonstrated faster and more pronounced effects on hip and femoral neck compared to teriparatide in early treatment months, potentially due to more selective PTH receptor binding [13]. The DATA-Switch study investigated teriparatide-to-denosumab sequencing, demonstrating continued substantial BMD increases across all skeletal sites. Over 48 months, this protocol resulted in 18.3% lumbar spine increase and 6.6% at total hip and 8.3% at femoral neck [17], representing one of the most potent sequential regimens documented, particularly for improving trabecular bone score reflecting microarchitectural quality [17]. Fracture Risk Reduction The ultimate metric of effectiveness in osteoporosis treatment is anti-fracture efficacy. A comprehensive meta-analysis of 69 trials involving over 80,000 patients confirmed that bone anabolic treatments are significantly more effective than bisphosphonates in preventing both vertebral and clinical fractures [18]. In active treatment comparisons, denosumab, PTH analogs, and romosozumab were all superior to oral bisphosphonates for vertebral protection. Specifically, parathyroid hormone receptor agonists were nearly 50% more effective in reducing clinical fractures compared to bisphosphonates (OR 1.49; 95% CI 1.12-2.00) [18]. The ARCH trial, following a sequential protocol of 12 months romosozumab followed by alendronate, demonstrated 48% reduction in new vertebral fracture risk compared to alendronate monotherapy [19]. Critically for orthopedic populations, hip fracture risk was reduced by 38% in the sequential group [19]. Table 3 summarizes the meta-analytic findings for vertebral fracture risk reduction. Table 3Meta-Analysis of relative risk for subsequent vertebral fractureComparisonRR (95% CI)EvidenceClinical ImplicationAnabolics vs. Bisphosphonates0.57 (0.45–0.71)HighAnabolics preferred for imminent risk [21]Teriparatide vs. Risedronate0.50 (0.37–0.68)HighSuperior vertebral protection [21]Denosumab vs. Placebo0.32 (0.26–0.41)HighStrong maintenance option [37]Data for patients with prevalent vertebral fractures [22]. Abbreviations: RR = relative risk; CI = confidence interval Meta-Analysis of relative risk for subsequent vertebral fracture Data for patients with prevalent vertebral fractures [22]. Abbreviations: RR = relative risk; CI = confidence interval The concept of imminent fracture risk is particularly relevant to orthopedic practice. Following a fragility fracture, the risk of a second fracture is highest in the subsequent two years [20]. Anabolic-first sequential therapy is uniquely suited for this crisis period because it induces rapid skeletal strengthening that antiresorptives cannot match [21]. In patients who have experienced osteoporotic vertebral fractures, anabolic agents provide superior prevention of subsequent fractures compared to bisphosphonates, although current evidence does not yet prove accelerated healing of the initial fracture [22]. Orthopedic Subspecialty Applications Hip Fracture Management Hip fractures represent arguably the most devastating complication of osteoporosis, associated with approximately 20% first-year mortality [20]. For survivors, morbidity is severe: fewer than half regain pre-fracture functional independence, and 45% have a history of prior fragility fracture indicating earlier intervention failure [23]. Recent studies have addressed the feasibility of sequential therapy in elderly hip fracture populations where long-term adherence to daily injections is challenging. An abbreviated sequential approach employing 3 to 6 months of anabolic agent (teriparatide or romosozumab) followed by denosumab demonstrated significant one-year postoperative BMD gains at lumbar spine (3.6%), femoral neck (4.4%), and total hip (1.9%) [24]. In contrast, non-sequential groups receiving only short-course anabolics without antiresorptive follow-up showed no significant changes at any site, underscoring the necessity of the consolidation step even when the anabolic phase is abbreviated for clinical practicality [24]. Spinal Reconstructive Surgery Adult spinal reconstructive surgery often involves multilevel instrumentation and fusion, procedures highly sensitive to surrounding bone quality [25]. The prevalence of unrecognized osteoporosis in this population is high, with up to 64% of patients unaware of their diagnosis prior to surgery [25]. Poor bone quality leads to specific mechanical failures including pedicle screw loosening, pseudarthrosis, and proximal or distal junctional kyphosis [25]. Teriparatide has emerged as the standard for pharmacologic optimization in spine surgery, with randomized studies demonstrating significantly higher fusion rates at 3D CT imaging as early as four months postoperatively, increased pedicle screw insertional torque, and promotion of active bone formation around hardware [25]. Total Joint Arthroplasty Total hip arthroplasty, while highly successful, faces long-term durability compromise from periprosthetic bone loss due to stress shielding, potentially causing 40% decline in proximal femoral BMD in the first postoperative year [26]. A network meta-analysis of 33 RCTs clarified comparative effectiveness in THA patients: for immediate postoperative preservation (6 months), denosumab was most efficient due to rapid RANKL pathway blockade; for intermediate-term preservation (12–24 months), combination approaches including teriparatide with alendronate outperformed monotherapies [26]. For patients with systemic osteoporosis undergoing THA, sequential therapy (anabolic followed by bisphosphonate) is considered optimal strategy to maximize both systemic and periprosthetic bone health [11]. Special Populations and Health Economics Osteoporosis in men is often underdiagnosed and undertreated despite higher hip fracture mortality rates compared to women (37.5% vs. 28.2% one-year mortality) [27]. The 2024 ESCEO guidelines specifically recommend sequential approach starting with bone-forming agents for men at very high risk, with abaloparatide now considered appropriate first-line treatment (weak recommendation) [27]. For glucocorticoid-induced osteoporosis, teriparatide has demonstrated superiority over alendronate in BMD outcomes and vertebral fracture reduction, with sequential teriparatide-to-denosumab showing significant femoral neck BMD increases not achieved with monotherapy [28]. The higher cost of anabolic agents drives step-therapy formulary preferences. However, lifetime cost-effectiveness analyses using microsimulation models demonstrate that sequential therapy often represents better long-term investment for high-risk patients [29]. Sequential abaloparatide followed by alendronate was found dominant compared to sequential teriparatide (more QALYs for lower cost) and cost-effective compared to alendronate monotherapy for men aged 50 + with prior hip or vertebral fracture [30]. These economic data suggest that step-therapy, while saving money short-term, may actually increase lifetime healthcare costs by failing to prevent expensive secondary fractures and nursing home admissions [29, 30]. Transition and Maintenance Strategies The literature consistently emphasized that osteoporosis requires lifelong management [4]. Bisphosphonates are typically used for 3 to 5 years, after which drug holidays may be considered for patients no longer at high risk [11]. However, drug holidays are strictly contraindicated for denosumab due to rebound phenomena [31]. Denosumab discontinuation triggers massive surge in bone turnover markers that can precipitate multiple spontaneous vertebral fractures [32]. The transition from denosumab to bisphosphonate must be timed precisely, with most experts recommending initiation approximately 6 to 7 months after the last denosumab dose [33]. Selective estrogen receptor modulators have been found ineffective in preventing bone loss after denosumab discontinuation, making bisphosphonates the only reliable bridging therapy currently available [33]. Discussion This scoping review synthesizes a substantial body of evidence supporting the superiority of sequential therapy over step-therapy approaches for osteoporosis management in high-risk populations. The findings carry particular significance for orthopedic subspecialties, where skeletal integrity directly determines the success of surgical interventions and patient outcomes. Several key themes emerge from this synthesis that merit focused discussion. First, the mechanistic rationale for anabolic-first sequencing is compelling and well-established. Antiresorptive agents stabilize existing bone but cannot restore lost microarchitecture, while anabolic agents actively build new trabecular and cortical bone that provides the structural foundation for subsequent consolidation [6, 10]. The blunting effect observed when anabolics follow prolonged antiresorptive therapy represents a meaningful limitation of the step-therapy paradigm, particularly at the hip where orthopedic surgeons most require robust bone quality [7, 8]. This mechanistic understanding should fundamentally reshape clinical decision-making: the sequence of therapy initiation matters as much as the choice of agents. Second, the magnitude of BMD differences between sequential and step-therapy approaches is clinically meaningful. The probability of achieving treat-to-target goals differs dramatically, from 92% versus 47% at the lumbar spine and 50% versus 5% at the total hip, suggesting that for many patients, step-therapy is mathematically incapable of achieving therapeutic targets within reasonable timeframes [15]. This has immediate implications for preoperative optimization in elective orthopedic surgery, where the window for bone strengthening may be limited. The goal-directed treatment paradigm advocated by ASBMR and BHOF task forces provides a pragmatic framework for operationalizing these findings, using total hip T-score as the treatment benchmark [34]. Third, the fracture risk reduction data support a fundamental reorientation of treatment priorities. The 48% reduction in vertebral fractures and 38% reduction in hip fractures demonstrated with romosozumab-to-alendronate sequencing in the ARCH trial represents meaningful protection that step-therapy approaches have not replicated [19]. For patients in the post-fracture period, when imminent risk is highest, the anabolic-first approach provides rapid skeletal strengthening that antiresorptives alone cannot achieve [20, 21]. Given that 45% of hip fracture patients have a history of prior fragility fracture, the persistence of step-therapy as standard practice represents a missed opportunity for secondary prevention [35]. Fourth, the orthopedic subspecialty applications of sequential therapy extend beyond simple fracture prevention. In hip fracture patients, abbreviated sequential protocols demonstrated feasibility in populations where adherence concerns are legitimate [24]. In spinal surgery, teriparatide improves fusion rates, screw purchase, and construct stability, outcomes directly relevant to surgical success [25]. In arthroplasty, sequential approaches optimize both systemic bone health and periprosthetic bone preservation [11, 26]. These findings suggest that osteoporosis management should be integrated into surgical planning rather than treated as an afterthought. The economic analyses provide important context for the policy debate surrounding step-therapy mandates. While anabolic agents have higher acquisition costs, lifetime microsimulation models demonstrate that sequential therapy is frequently cost-effective or even dominant (providing more QALYs at lower cost) compared to step-therapy approaches [29, 30]. The short-term cost savings achieved through step-therapy may be illusory when the downstream costs of secondary fractures, surgical complications, and nursing home admissions are considered [29, 30]. This finding should inform payer policies and prior authorization requirements that currently create barriers to appropriate care. Limitations This review has several limitations that warrant acknowledgment. The included studies exhibited heterogeneity in patient populations, intervention protocols, outcome measures, and follow-up durations, limiting direct comparability. Much of the evidence derives from postmenopausal women, with men and secondary osteoporosis populations underrepresented. The treat-to-target paradigm, while conceptually compelling, lacks long-term validation studies confirming that achieving specific T-score thresholds translates to sustained fracture risk reduction. Additionally, the optimal duration of anabolic therapy before transition, the choice of antiresorptive for consolidation, and the management of patients who fail sequential therapy remain areas requiring further investigation. Finally, while cost-effectiveness analyses support sequential therapy, these models depend on assumptions that may not generalize across healthcare systems and populations. Future Directions Future research should prioritize head-to-head comparisons of specific sequential regimens, standardized outcome measures across orthopedic subspecialties, long-term safety data for extended treatment durations, and real-world effectiveness studies examining implementation barriers. The development of biomarkers predicting individual response to sequential versus step-therapy approaches could enable precision medicine strategies. Additionally, comparative effectiveness research examining abbreviated sequential protocols in frail elderly populations would address a significant evidence gap. Finally, health systems research examining the impact of formulary policies on treatment patterns and outcomes would provide the evidence base needed to inform policy reform(Fig. 1). Pharmacologic mechanisms of major osteoporosis therapies. Schematic of the bone remodeling pathways targeted by osteoporosis medications. Bisphosphonates inhibit osteoclast-mediated bone resorption and promote osteoclast apoptosis; denosumab suppresses RANKL-mediated osteoclast differentiation and activation; PTH analogs (teriparatide and abaloparatide) stimulate osteoblast-lineage activity and bone formation; and romosozumab inhibits sclerostin, increasing bone formation while reducing bone resorption. HSC = hematopoietic stem cell; MSC = mesenchymal stem cell Conclusion The evidence synthesized in this scoping review supports the superiority of anabolic-first sequential therapy over traditional step-therapy approaches for osteoporosis management in high-risk populations. Sequential therapy achieves greater BMD gains, higher probability of reaching treatment targets, and superior fracture risk reduction compared to step-therapy, while the blunting effect compromises the effectiveness of anabolic agents when administered after prolonged antiresorptive exposure. For orthopedic subspecialty populations, including those undergoing hip fracture management, spinal reconstructive surgery, and total joint arthroplasty, the sequential approach should be considered the standard of care. The integration of goal-directed osteoporosis treatment into surgical planning, utilizing total hip T-score as the treatment benchmark, provides a pragmatic framework for achieving these outcomes. While anabolic agents carry higher acquisition costs, lifetime cost-effectiveness analyses support their use in high-risk patients. Clinical practice guidelines and formulary policies should be updated to reflect this evidence, removing barriers that perpetuate suboptimal step-therapy approaches and contribute to the persistent treatment gap in osteoporosis care. Key References 15. Cosman F, Oates M, Betah D, Timoshanko J, Wang Z, Ferrari S, et al. Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension. J Bone Miner Res. 2024;39(9):1268–1277.○ This post hoc analysis provides a direct comparison of anabolic-first sequential therapy versus antiresorptive monotherapy, showing approximately two-fold greater bone mineral density gains at the lumbar spine, total hip, and femoral neck with romosozumab followed by denosumab. It provides key quantitative support for sequencing strategies aimed at maximizing early skeletal gains before antiresorptive consolidation. 15. Cosman F, Oates M, Betah D, Timoshanko J, Wang Z, Ferrari S, et al. Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension. J Bone Miner Res. 2024;39(9):1268–1277.○ This post hoc analysis provides a direct comparison of anabolic-first sequential therapy versus antiresorptive monotherapy, showing approximately two-fold greater bone mineral density gains at the lumbar spine, total hip, and femoral neck with romosozumab followed by denosumab. It provides key quantitative support for sequencing strategies aimed at maximizing early skeletal gains before antiresorptive consolidation. ○ This post hoc analysis provides a direct comparison of anabolic-first sequential therapy versus antiresorptive monotherapy, showing approximately two-fold greater bone mineral density gains at the lumbar spine, total hip, and femoral neck with romosozumab followed by denosumab. It provides key quantitative support for sequencing strategies aimed at maximizing early skeletal gains before antiresorptive consolidation. ○ This post hoc analysis provides a direct comparison of anabolic-first sequential therapy versus antiresorptive monotherapy, showing approximately two-fold greater bone mineral density gains at the lumbar spine, total hip, and femoral neck with romosozumab followed by denosumab. It provides key quantitative support for sequencing strategies aimed at maximizing early skeletal gains before antiresorptive consolidation. 18. Händel MN, Cardoso I, von Bülow C, Rohde JF, Ussing A, Nielsen SM, et al. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ. 2023;381:e068033.○ This network meta-analysis provides a broad comparative synthesis of fracture outcomes across osteoporosis therapies, showing favorable vertebral and hip fracture prevention profiles for anabolic and dual-action agents. It serves as an important comparative-efficacy reference for treatment selection in high-risk patients. 18. Händel MN, Cardoso I, von Bülow C, Rohde JF, Ussing A, Nielsen SM, et al. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ. 2023;381:e068033.○ This network meta-analysis provides a broad comparative synthesis of fracture outcomes across osteoporosis therapies, showing favorable vertebral and hip fracture prevention profiles for anabolic and dual-action agents. It serves as an important comparative-efficacy reference for treatment selection in high-risk patients. ○ This network meta-analysis provides a broad comparative synthesis of fracture outcomes across osteoporosis therapies, showing favorable vertebral and hip fracture prevention profiles for anabolic and dual-action agents. It serves as an important comparative-efficacy reference for treatment selection in high-risk patients. ○ This network meta-analysis provides a broad comparative synthesis of fracture outcomes across osteoporosis therapies, showing favorable vertebral and hip fracture prevention profiles for anabolic and dual-action agents. It serves as an important comparative-efficacy reference for treatment selection in high-risk patients. 21. Jeon I, Park SB, Moon BJ, Choi M, Kuh SU, Kim J. Comparison of the clinical efficacy of anabolic agents and bisphosphonates in the patients with osteoporotic vertebral fracture: systematic review and meta-analysis of randomized controlled trials. Neurospine. 2024;21(2):416–429.○ This meta-analysis is a highly orthopedic-relevant synthesis showing that anabolic therapy was associated with a lower risk of subsequent vertebral fracture than bisphosphonates among patients with prevalent vertebral fractures (relative risk, 0.57). It provides important evidence supporting anabolic prioritization in spine-focused high-risk populations and supports the comparative data summarized in Table 3. 21. Jeon I, Park SB, Moon BJ, Choi M, Kuh SU, Kim J. Comparison of the clinical efficacy of anabolic agents and bisphosphonates in the patients with osteoporotic vertebral fracture: systematic review and meta-analysis of randomized controlled trials. Neurospine. 2024;21(2):416–429.○ This meta-analysis is a highly orthopedic-relevant synthesis showing that anabolic therapy was associated with a lower risk of subsequent vertebral fracture than bisphosphonates among patients with prevalent vertebral fractures (relative risk, 0.57). It provides important evidence supporting anabolic prioritization in spine-focused high-risk populations and supports the comparative data summarized in Table 3. ○ This meta-analysis is a highly orthopedic-relevant synthesis showing that anabolic therapy was associated with a lower risk of subsequent vertebral fracture than bisphosphonates among patients with prevalent vertebral fractures (relative risk, 0.57). It provides important evidence supporting anabolic prioritization in spine-focused high-risk populations and supports the comparative data summarized in Table 3. ○ This meta-analysis is a highly orthopedic-relevant synthesis showing that anabolic therapy was associated with a lower risk of subsequent vertebral fracture than bisphosphonates among patients with prevalent vertebral fractures (relative risk, 0.57). It provides important evidence supporting anabolic prioritization in spine-focused high-risk populations and supports the comparative data summarized in Table 3. 34. Cosman F, Lewiecki EM, Eastell R, Ebeling PR, Jan de Beur S, Langdahl B, et al. Goal-directed osteoporosis treatment: a progress report from the ASBMR/BHOF Task Force. J Bone Miner Res. 2024;39(10):1393–1405.○ This Task Force report identifies total hip T-score as a treatment target and advances a goal-directed framework that positions sequencing decisions around measurable bone mineral density endpoints rather than a fixed drug hierarchy. It provides the clinical framework supporting anabolic-first initiation in high-risk surgical populations and helps contextualize the manuscript’s Discussion. 34. Cosman F, Lewiecki EM, Eastell R, Ebeling PR, Jan de Beur S, Langdahl B, et al. Goal-directed osteoporosis treatment: a progress report from the ASBMR/BHOF Task Force. J Bone Miner Res. 2024;39(10):1393–1405.○ This Task Force report identifies total hip T-score as a treatment target and advances a goal-directed framework that positions sequencing decisions around measurable bone mineral density endpoints rather than a fixed drug hierarchy. It provides the clinical framework supporting anabolic-first initiation in high-risk surgical populations and helps contextualize the manuscript’s Discussion. ○ This Task Force report identifies total hip T-score as a treatment target and advances a goal-directed framework that positions sequencing decisions around measurable bone mineral density endpoints rather than a fixed drug hierarchy. It provides the clinical framework supporting anabolic-first initiation in high-risk surgical populations and helps contextualize the manuscript’s Discussion. ○ This Task Force report identifies total hip T-score as a treatment target and advances a goal-directed framework that positions sequencing decisions around measurable bone mineral density endpoints rather than a fixed drug hierarchy. It provides the clinical framework supporting anabolic-first initiation in high-risk surgical populations and helps contextualize the manuscript’s Discussion. Acknowledgements None. Author contributions SGS & RP conceived the study design; RP, SGS, and JB carried out data collection, interpretation & analysis, manuscript drafting & revisions; JW supervised the study design and manuscript revision. All authors reviewed and approved the final version of the manuscript. Funding This research received no external funding. Data Availability No datasets were generated or analysed during the current study. Declarations Institutional Review Board Statement Not applicable. Informed Consent Statement Waived. Competing Interests The authors declare no competing interests. Conflict of Interest The authors declare no conflict of interest. Footnotes Samer G. Salman and Rohan Phadke contributed equally. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Samer G. Salman, Email: samer.salman@bcm.edu Rohan Phadke, Email: rohan.phadke@bcm.edu. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.